← Leaderboards
Lisa Hammond
University Of Texas Hlth Sci Ctr San Ant
$720,920
Attributed
$720,920
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$720,920 · 4
By mechanism
M01$720,920 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Eric K Rowinsky$9,623,858
- Brian A. Herman$12,167,012
- Sang Eun Lee$7,736,394
- Karl E Klose$6,535,684
- Natalie S Callender$0
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationDrug Screening /EvaluationClinical ResearchHuman SubjectPharmacokineticsClinical Trial Phase INeoplasm /Cancer ChemotherapyDosageDrug Adverse EffectDna ReplicationDrug InteractionsEnzyme ActivityGrowth InhibitorsPlant ExtractsAlkylating AgentsAntineoplasticsBreast NeoplasmsCancer ComplicationCarcinogenesis InhibitorCarmustineCell Growth RegulationCombination ChemotherapyLiver MetabolismMetastasis
Grant awards (16)
PHASE I OF BCNU AND TEMOZOLOMIDE$234,837
M01 · FY2002 · RR
PHASE I OF BCNU AND TEMOZOLOMIDE$234,837
M01 · FY2002 · RR
PHARMACOKINETICS OF NSC 655649 SEQUENCES AND CISPLATIN$0
M01 · FY2002 · RR
IRINOTECAN IN REFRACTORY SOLID TUMOR WITH LIVER DISORDER$0
M01 · FY2002 · RR
IRINOTECAN IN REFRACTORY SOLID TUMOR WITH LIVER DISORDER$0
M01 · FY2002 · RR
MGI 114 IN PATIENTS WITH METASTATIC BREAST CANCER$0
M01 · FY2002 · RR
MGI 114 IN PATIENTS WITH METASTATIC BREAST CANCER$0
M01 · FY2002 · RR
PHARMACOKINETICS OF NSC 655649 SEQUENCES AND CISPLATIN$0
M01 · FY2002 · RR
PHASE I OF BCNU AND TEMOZOLOMIDE$234,837
M01 · FY2001 · RR
PHARMACOKINETICS OF NSC 655649 SEQUENCES AND CISPLATIN$0
M01 · FY2001 · RR
IRINOTECAN IN REFRACTORY SOLID TUMOR WITH LIVER DISORDER$0
M01 · FY2001 · RR
MGI 114 IN PATIENTS WITH METASTATIC BREAST CANCER$0
M01 · FY2001 · RR
PHASE I OF BCNU AND TEMOZOLOMIDE$16,409
M01 · FY2000 · RR
IRINOTECAN IN REFRACTORY SOLID TUMOR WITH LIVER DISORDER$0
M01 · FY2000 · RR
MGI 114 IN PATIENTS WITH METASTATIC BREAST CANCER$0
M01 · FY2000 · RR
PHARMACOKINETICS OF NSC 655649 SEQUENCES AND CISPLATIN$0
M01 · FY2000 · RR